Ambros Therapeutics raised $154 million to advance late-stage development and U.S. regulatory approval of neridronate, a treatment for a rare chronic pain condition known as complex regional pain syndrome Type I.
Ambros Therapeutics raised $154 million to advance late-stage development and U.S. regulatory approval of neridronate, a treatment for a rare chronic pain condition known as complex regional pain syndrome Type I.